Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, Pavlov KH, Petrovic A, Sikiric S, Vranes H, Prtoric A, Zizek H, Durasin T, Dobric I, Staresinic M, Strbe S, Knezevic M, Sola M, Kokot A, Sever M, Lovric E, Skrtic A, Blagaic AB, Sikiric P
63 (22), e1900492
The impact of xanomeline and trospium chloride on cognitive impairment in acute schizophrenia: replication in pooled data from two phase 3 trials
Eguchi S, Kamlot A, Ljubimova J et al
doi: 10.1111/j.1753-4887.2008.00031.x

Mold Immune Reactivity IgE: Cladosporium herbarum : 2.4 Penicillium chrysogen : 4.1 Remaining panel: negative IgG: Broad elevation across multiple molds (including Cladosporium, Aspergillus, Setomelanomma, Curvularia ) Clinical Interpretation of Findings Indicated: Strong mold-specific immune sensitization Intermediate Intervention: Immune Modulation and Neuroregulation Oral immunotherapy (1 5 drops over 5 weeks) L-theanine 200 mg three times daily Clinical Response: Substantial reduction in anxiety Improved cognitive clarity Improved emotional stability Escalation of Binding Therapy Cholestyramine introduced Clinical Response (2 months): Resolution of fatigue Resolution of pain Improved GI symptoms Reduced food intolerance Final Intervention: Glutathione IV glutathione titrated from 1000 mg 3000 mg over 6 weeks Clinical Response: Resolution of insomnia Outcome Neuropsychiatric symptoms resolved Systemic symptoms improved Sleep normalized Discussion Objective improvement may precede symptom resolution Early reductions in C4a and TGF-1 suggest physiologic improvement before full clinical recovery
